Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for lymphoma in seniors

NCT ID NCT00690560

Disease control Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a treatment plan for adults aged 65 to 80 with a type of lymphoma (large B-cell). The plan combined standard chemotherapy with targeted antibodies and a radioactive drug. The goal was to see if this approach could better control the cancer. The study involved 30 participants and found that most responded well, though some had side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

30 people

The number who actually took part.

Start date

May 2007

Finished

Oct 2010

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

DISEASE CHARACTERISTICS: * Histologically confirmed large B-cell lymphoma * Stage I, II, III, or IV disease * Bone marrow or lymph node involvement by small cell lymphoma allowed * No serious, progressive pathology (at investigator's discretion) * CD20-positive disease * Measurable disease * No prior indolent lymphoma, treated or not * No meningeal or CNS lymphoma PATIENT CHARACTERISTICS: * International prognostic index \< 2 (adjusted for age) * Life expectancy \> 3 months * ALT and AST ≤ 2.5 times upper limit of normal * Bilirubin ≤ 30 mmol/L * Creatinine ≤ 150 μmol/L * HIV, hepatitis B virus, and hepatitis C virus negative (unless after vaccine) * No contraindication to chemotherapy or immunotherapy * No cancer in the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix * No contraindication to a venous catheter PRIOR CONCURRENT THERAPY: * See Disease Characteristics * At least 30 days since prior and no other concurrent investigational treatment * No prior therapy * No concurrent participation in another clinical study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma large B-cell lymphoma lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma

Contacts and locations

Locations

  • Centre Antoine Lacassagne

    Nice, 06189, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.